How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

Sulopenem is Noninferior to Amoxicillin/Clavulanate For Uncomplicated UTIs

Pharmacist-Led Review Uncovers Frequent ART Errors in Hospitalized Adults With HIV

How Can Scientists and Investigators Find Funding Today?

Antibody Levels Below Traditional Threshold Still Protect Against Hepatitis B in Vaccinated Children

Global Burden Study Highlights Underappreciated Adult RSV Hospitalizations

Considering the Value of Antiviral Resistance Testing in Certain Populations

Cidara’s CD388 Demonstrates Up to 76% Protection Against Influenza in Phase 2b NAVIGATE Trial

ASM Microbe Conference: ‘Great Migration of Microbiologists’

A Pioneer in Coronavirus Research

Airborne Fungal Spores May Predict Short-Term Surges in COVID-19 and Influenza

Schedule an Appointment

Quick Links

Patient Forms

Contact Us